Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
Diencephalic syndrome
Diencephalic syndrome
Diencephalic syndrome
Synonyms: Diencephalic cachexia, Diencephalic syndrome of childhood, Diencephalic syndrome of emaciation, Russell diencephalic cachexia, Russell syndrome
Synonyms: Diencephalic cachexia, Diencephalic syndrome of childhood, Diencephalic syndrome of emaciation, Russell diencephalic cachexia, Russell syndrome
Synonyms: Diencephalic cachexia, Diencephalic syndrome of childhood, Diencephalic syndrome of emaciation, Russell diencephalic cachexia, Russell syndrome
Drug discovery
60
papers
On emerging therapies
Rare endocrine diseases
Diencephalic syndrome
Overview
Diencephalic syndrome (DS) is a rare, tumor-associated disorder characterized by severe emaciation despite normal caloric intake, hyperactivity, euphoria, and normal linear growth. Caused predominantly by hypothalamic/optic pathway gliomas, it manifests with hypothalamic dysfunction, visual abnormalities, and metabolic disturbances (e.g., elevated growth hormone, reduced leptin). Diagnosis relies on MRI and ophthalmologic evaluation, with leptomeningeal spread common. Untreated, survival is <12 months, but multimodal therapy improves outcomes [1][2][6][10].
Categories: rare endocrine diseases
Research Papers
60 drug discovery papers about Diencephalic syndrome. Recent publications:
60 drug discovery papers about Diencephalic syndrome. Recent publications:
categories:
Small molecules
small molecules
2026-06-23 | ID #974 Diencephalic syndrome in an infant with low grade glioma refractory to chemotherapy a dramatic and sustained response to tovorafenib
Abstract Background Diencephalic syndrome is a rare but severe presentation of pediatric low-grade glioma (LGG), often associated with hypothalamic and optic pathway tumors in infancy and early childhood[1]. It is characterized by profound failure to thrive despite adequate caloric intake, with relative preservation of linear growth. Management is challenging, and responses to conventional chemotherapy are variable[2]. Despite low-grade histology, infant LGG with diencephalic syndrome is associated with poorer outcomes, with 5-year PFS of approximately 20%[3]. Methods We report the case of an infant diagnosed at three months of age with a large hypothalamic/optic pathway tumor with solid and cystic components, presenting with profound failure to thrive consistent with diencephalic syndrome. He underwent resection of large cystic components of the tumor and biopsy, which confirmed the diagnosis of pilomyxoid astrocytoma with a KIAA1549-BRAF fusion. Results The patient was treated with carboplatin for two months but showed early radiographic progression and leptomeningeal dissemination. Despite enteral nutritional support, he continued to show poor weight gain. Subsequent switch to vinblastine therapy failed to halt clinical or radiographic progression. In the setting of chemotherapy refractory disease, tovorafenib was initiated at six months of age. This resulted in rapid radiographic response after six weeks of treatment, associated with significant improvement in weight. Radiographic response was sustained, with improvement in both solid and cystic components of the tumor. While the patient tolerated treatment well without significant side effects, he experienced significant decrease in growth velocity while on therapy, a known side effect of tovorafenib. Conclusions This case highlights the potential for tovorafenib to induce rapid and meaningful clinical and radiographic responses in infants with diencephalic syndrome and refractory BRAF-altered low-grade glioma. Targeted therapy may represent an important treatment option for this high-risk population and is currently being evaluated in a phase 3 clinical trial. 1. Poussaint, T. Y., Barnes, P. D., Nichols, K., Anthony, D. C., Cohen, L., Tarbell, N. J., & Goumnerova, L. (1997). Diencephalic syndrome: clinical features and imaging findings. AJNR. American journal of neuroradiology, 18(8), 1499–1505. 2. Mirow, C., Pietsch, T., Berkefeld, S., Kwiecien, R., Warmuth-Metz, M., Falkenstein, F., Diehl, B., von Hornstein, S., & Gnekow, A. K. (2014). Children <1 year show an inferior outcome when treated according to the traditional LGG treatment strategy: a report from the German multicenter trial HIT-LGG 1996 for children with low grade glioma (LGG). Pediatric blood & cancer, 61(3), 457–463. https://doi.org/10.1002/pbc.24729 3. Kilday, J. P., Bartels, U., Huang, A., Barron, M., Shago, M., Mistry, M., Zhukova, N., Laperriere, N., Dirks, P., Hawkins, C., Bouffet, E., & Tabori, U. (2014). Favorable survival and metabolic outcome for children with diencephalic syndrome using a radiation-sparing approach. Journal of neuro-oncology, 116(1), 195–204. https://doi.org/10.1007/s11060-013-1284-2
2026-06-19 | Clinical application of diffusion tensor tractography in classification of pediatric optic chiasmatic gliomas: a retrospective cohort study.
The classification based on diffusion tensor tractography (DTT) has already been applied to the assessment of the optic chiasmatic glioma (OCGs), but the value of clinical application remains controversial. This study aimed to evaluate the predictive value of DTT classification for clinical phenotypes and to investigate the prognostic factors in children with OCGs. A total of 53 patients with OCGs diagnosed and admitted between July 2015 and November 2022 were included. Clinical parameters were collected from medical records. The prognosis analysis comprised clinical, endocrinologic, ophthalmologic and pathologic during different time spans. On DTT images, the tumors were divided into the inflating endophytic type, the inflating exogenous type, and the infiltrative endophytic type based on DTT features. Regression analysis detected the evaluation of classifications which was assessed by determining age, gender, weight, diencephalic syndrome diagnosis record, vision-related data, endocrine-related indicators, surgery related indicators, survival data, chemotherapy, and radiotherapy. We observed that the proportion of males in the inflating exogenous type patients (10%) was significantly lower than other two types. The inflating endophytic type patients (median 9.5 kg, 4.2∼25.4 kg) had lower body weight at surgery than other two types, as well as higher prevalence of diencephalic syndrome (DS). Postoperative chemotherapy demonstrated a statistically significant protective effect on OS and EFS (p = 0.032 and 0.017, respectively). The DTT-based classification effectively identifies the inflating endophytic subtype, which is associated with a high incidence of diencephalic syndrome, and serves as a valuable tool for preoperative surgical guidance. Combined adjuvant chemotherapy represents a decisive therapeutic strategy that significantly prolongs long-term prognosis in pediatric OCG patients.
2026-02-27 | Diencephalic Syndrome: Clinical Features, Pathophysiology, and Long-Term Outcomes.
Background/Objectives: Diencephalic syndrome (DS) is an uncommon pediatric disorder presenting with severe failure to thrive despite adequate caloric intake and preserved linear growth. First characterized by Russell, this condition predominantly affects infants under 12 months and remains diagnostically challenging. Methods: We performed a comprehensive literature review examining clinical presentation, underlying pathophysiology, associated pathology, diagnostic approaches, and long-term outcomes of DS. Results: DS typically manifests in the first year of life with profound cachexia, normal or increased appetite, preserved height velocity, and characteristic features including hyperactivity, euphorism, and visual pathway involvement. Low-grade gliomas of the hypothalamic-chiasmatic region, particularly pilocytic astrocytomas, represent the predominant underlying pathology. The pathophysiological mechanisms remain incompletely understood but likely involve complex dysregulation of hypothalamic energy homeostasis. While overall survival exceeds 90% at five years, most patients experience significant long-term morbidity including visual impairment, multiple endocrine deficiencies, and hypothalamic obesity. Diagnostic delays averaging 11 months contribute to irreversible complications. Conclusions: Early recognition of DS is essential to prevent permanent visual loss and optimize outcomes. Multidisciplinary management incorporating chemotherapy as first-line treatment for underlying gliomas has improved survival while reducing radiation-associated toxicities. However, survivors face substantial lifelong sequelae requiring comprehensive monitoring and intervention. Future research should focus on elucidating precise pathophysiological mechanisms, developing targeted molecular therapies, and improving management of hypothalamic obesity and other late effects.
2025-05-19 | Skeletal stem/progenitor cell-derived rather than osteoblast-derived IGF2 supports the development and homeostasis of skeletal system via STAT3.
Rationale: Skeletal deformities are characteristic manifestations of Silver-Russell Syndrome with mutations in insulin-like growth factor 2 (IGF2) gene serving as the most prevalent genetic abnormality. However, the mechanism by which IGF2 influence bone development and homeostasis remains unclear. Besides, the expression pattern of Igf2 and the local cells-derived Igf2 at cellular level within bone microenvironment also lacked research. Methods: ScRNA-seq analysis was obtained from Gene Expression Omnibus (GEO) and analyzed to discover the expression pattern of Igf2. Then, mice models of specific deletion of Igf2 in three different cell types by crossing Igf2 flox with Osxcre , Prx1cre and Ocncre mice respectively were established. The skeletal systems of these mice were analyzed, along with the in vitro osteogenic capacity of their bone marrow-derived mesenchymal stem cells (BMSCs). Lastly, RNA-sequencing (RNA-seq) was carried out to elucidate the underlying mechanisms, and administration of an agonist targeting the key molecule was also undertaken. Results: Igf2 was enriched in skeletal stem/progenitor cells (SSPCs) rather than osteoblasts and we have observed deformities in the femur and other skeletons in OsxCre; Igf2fl/-, Prx1Cre; Igf2fl/- but not OcnCre; Igf2fl/- mice and the deformities were induced by a reduction in osteogenesis with minimal changes in osteoclastogenesis. It is further revealed that Igf2 deletion impaired the osteogenesis via STAT3 and pharmacological activation of STAT3 could reverse the skeletal deformities. Conclusions: In summary, these finding reveals that IGF2 derived from SSPCs, rather than osteoblasts, supports the development and homeostasis of skeletal system via STAT3 signaling and targeting STAT3 might be a promising therapeutic strategy for SRS-related skeletal deformities.
2023-09-30 | Cyproheptadine as an appetite stimulant in children. Is it safe?
Background: Cyproheptadine as an appetite stimulant in children. Is it safe? This drug has been used to increase appetite in pediatric patients, regardless of their sex or the presence of pathological conditions. The effectiveness of this drug in terms of weight gain and growth is still a matter of interest. due to the diversity of conclusions regarding its mechanism of action and therapeutic results. Methods: This bibliographic review of the scientific literature focused on research in order to obtain results around scientific articles related to the use of cyproheptadine as an appetite stimulant in pediatric patients. Results: all the articles analyzed concluded that cyproheptadine is an effective medication for weight gain in pediatric patients, based on appetite stimulation, totally independent of sex and the presence of pathological states. Conclusions: Cyproheptadine is a safe medication, and adequately tolerated in all pediatric patients. It is possible to measure the improvement in weight and growth indices in patients under twelve years of age, if consumption is for at least four consecutive weeks.
antibodies
2025-09-23 | Exploring the coexistence of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis and demyelinating disorders in a pediatric case
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an immune-mediated disorder characterized by a complex neuropsychiatric syndrome and the presence of cerebrospinal fluid antibodies targeting the GluN1 subunit of the NMDAR. While well-documented, its association with demyelinating disorders—such as neuromyelitis optica, myelitis, and acute disseminated encephalomyelitis—remains rare, particularly in pediatric cases. Here, we present an unusual case of a 7-year-old female who initially exhibited area postrema syndrome, followed by acute brainstem syndrome and encephalopathy. Over two subsequent relapses within 2 years, she developed longitudinally extensive transverse myelitis, seizures, and diencephalic syndrome, alongside mild contrast-enhancing lesions in both infratentorial and supratentorial regions. Despite repeated testing, both antibodies to myelin-oligodendrocyte glycoprotein and aquaporin-4 remained negative. Subsequently, a comprehensive antibody testing protocol, including indirect immunohistochemistry on rat brain tissue and an extensive panel of both fixed and live cell-based assays was requested, confirming the presence of anti-NMDAR antibodies, along with superimposed reactivity to cerebellar granular cells. This report explores the diagnostic and therapeutic complexities of coexisting anti-NMDAR encephalitis and demyelinating disorders. The rarity of this overlap and its distinct clinical features underscore the need for further research into the immunological mechanisms underlying these conditions. • Diagnostic delay and misrecognition are common in overlapping anti-NMDAR encephalitis and demyelinating disorders, especially when initial symptoms resemble conditions such as ADEM or NMOSD. • Anti-NMDAR encephalitis should be considered in pediatric demyelinating cases presenting with prominent psychiatric or behavioral symptoms. • Long-term monitoring is essential in overlapping autoimmune syndromes due to the potential for recurrence driven by distinct immune pathways.
2024-09-25 | Diencephalic syndrome in a child with chronic malnutrition.
Russell's diencephalic syndrome is a set of signs and symptoms characterized by extreme weight loss, with no impairment of height or head circumference, without changes in intake or appetite. It is due to hypothalamic dysfunction associated with space-occupying lesions in this region. It is a rare cause of malnutrition in pediatrics, so its diagnosis is often delayed. Here we describe the case of a 17-month-old male patient with weight loss for 3 months who was admitted to the pediatric inpatient ward due to suspected intestinal malabsorption syndrome. After ruling out the most common causes of malnutrition, the patient was diagnosed with pilomyxoid astrocytoma of the brainstem.
2016-05-02 | Anti-N-methyl- d -aspartate receptor encephalitis in a patient with neuromyelitis optica spectrum disorders
We described a female patient with anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis occurring sequentially with neuromyelitis optica spectrum disorders (NMOSD). The 19-year-old patient initially presented a diencephalic syndrome with aquaporin-4 immunoglobulin G antibodies (AQP4-IgG) and brain lesions which involving bilateral medial temporal lobes and periependymal surfaces of the third ventricle on magnetic resonance imaging (MRI). Ten months later, the patient developed cognitive impairment, psychiatric symptoms and dyskinesia with left basal ganglia lesions on brain MRI. Meanwhile, the anti-NMDAR antibodies were positive in the patient's serum and cerebrospinal fluid, while the screening tests for an ovarian teratoma and other tumors were all negative. Hence, the patient was diagnosed NMOSD and anti-NMDAR encephalitis followed by low-dose rituximab treatment with a good response. This case was another evidence for demyelinating syndromes overlapping anti-NMDAR encephalitis in Chinese patients.
2013-09-04 | Children <1 year show an inferior outcome when treated according to the traditional LGG treatment strategy: A report from the german multicenter trial HIT-LGG 1996 for children with low grade glioma (LGG)
Background Children diagnosed with LGG at an age <1 year are reported to have an impaired prognosis in comparison to older patients. Analysis of this subgroup could reveal the necessity to develop risk-adapted treatment approaches. Procedure Children <1 year at diagnosis (n = 66, median age 7.3 months, 33 female, none NFI) from the HIT-LGG 1996 cohort were analyzed for risk factors for EFS, PFS and OS. Several children suffered from diencephalic syndrome (DS, n = 22) and primary dissemination (DLGG, n = 9), 50 had a supratentorial midline (SML) location. Extent of resection was complete/subtotal in 12, partial in 15, biopsy in 27. Tumors were pilocytic astrocytoma WHO grade I (n = 33), other WHO grade I (n = 14), pilomyxoid astrocytomas WHO grade II (n = 3), and neuroepithelial tumors WHO grade II (n = 4). Results One-year EFS was 34.8%. SML-localisation, minor extent of surgery, pilocytic astrocytoma, DLGG and DS were unfavorable predictive factors. No additional non-surgical therapy was applied in 24, 36 were treated with VCR/carboplatin chemotherapy, 6 with radiotherapy (5/6 brachytherapy). Ten-year-PFS-rate following non-surgical therapy was 16.7%; DS and DLGG were unfavorable factors. Ten-year-OS-rate was 72.8%, lower for children <6 months at diagnosis, with DS, or with DLGG. At last follow up in August 2011, vision in 31 living children was often severely impaired. Conclusions Children <1 year at diagnosis have a conspicuously impaired survival with current treatment approaches. Age <6 months, diencephalic syndrome and dissemination constitute risk factors for even lower PFS and OS. Treatment adaptations are needed to improve outcome and molecular genetics may explain tumor aggressiveness. Pediatr Blood Cancer 2014;61:457–463. © 2013 Wiley Periodicals, Inc.
2011-06-07 | Narcolepsy, REM sleep behavior disorder, and supranuclear gaze palsy associated with Ma1 and Ma2 antibodies and tonsillar carcinoma.
To describe a patient with diencephalic and mesencephalic presentation of a Ma1 and Ma2 antibody-associated paraneoplastic neurological disorder. Case report. The Colorado Neurological Institute Movement Disorders Center in Englewood, Colorado, and the Mayo Clinic in Rochester, Minnesota. A 55-year-old man with a paraneoplastic neurological disorder characterized by rapid eye movement sleep behavior disorder, narcolepsy, and a progressive supranuclear palsy-like syndrome in the setting of tonsillar carcinoma. Immunotherapy for paraneoplastic neurological disorder, surgery and radiotherapy for cancer, and symptomatic treatment for parkinsonism and sleep disorders. Polysomnography, multiple sleep latency test, and neurological examination. The cancer was detected at a limited stage and treatable. After oncological therapy and immunotherapy, symptoms stabilized. Treatment with modafinil improved daytime somnolence. Rapid onset and progression of multifocal deficits may be a clue to paraneoplastic etiology. Early treatment of a limited stage cancer (with or without immunotherapy) may possibly slow progression of neurological symptoms. Symptomatic treatment may be beneficial.
proteins
2025-11-20 | Growth hormone therapy in high-risk pediatric populations: Integrated growth, metabolic, and safety outcomes in SGA, preterm, and Russell–silver syndrome
Background: Growth hormone (GH) therapy is widely used to enhance growth outcomes in children with growth disorders, including those born small for gestational age (SGA), preterm infants, and individuals with Russell-Silver Syndrome (RSS). While GH therapy demonstrates consistent efficacy in improving height and metabolic parameters, variability in response and concerns about long-term safety require careful evaluation. Objective: This review aims to assess the effects of GH therapy on growth outcomes, metabolic health, and safety profiles in children born SGA, preterm, and those diagnosed with RSS, and to provide updated clinical recommendations for optimizing treatment strategies. Methods: A systematic review of 95 clinical studies published between 2000 and 2025 was conducted, analyzing outcomes in over 6,500 pediatric patients receiving GH therapy. Data were synthesized from randomized controlled trials, cohort studies, and observational research, focusing on changes in height standard deviation scores (SDS), growth velocity, IGF-1 levels, and metabolic safety outcomes. Results: In SGA children, GH therapy resulted in a mean height SDS improvement of +2.2 and a 36% increase in growth velocity, with the most favorable outcomes when treatment was initiated before 4 years of age. Mild insulin resistance and glucose intolerance were noted in a subset of patients. Preterm infants demonstrated an average height SDS gain of +1.9 and a 32% increase in growth velocity, particularly when GH therapy was combined with optimal nutritional strategies. Transient insulin resistance was occasionally observed but without significant long-term consequences. In RSS patients, GH therapy improved height SDS by +1.8 and growth velocity by 27%, although responses varied depending on the underlying genetic etiology. Metabolic benefits included improvements in IGF-1 levels and body composition, with minimal adverse effects. Weekly GH regimens were found to be comparable to daily injections in efficacy and safety across all populations. Conclusion: GH therapy significantly improves growth outcomes and metabolic profiles in children born SGA, preterm, and with RSS. Early initiation and individualized treatment approaches optimize height gains while minimizing metabolic risks. Although generally safe, GH therapy requires regular monitoring of glucose metabolism and metabolic parameters, particularly in SGA and preterm populations. Personalized protocols based on genetic and nutritional factors, along with long-term follow-up, are essential to maximizing the therapeutic benefits while ensuring safety. Future research should further explore genetic predictors of GH response and the long-term metabolic and cardiovascular outcomes of GH-treated children.
2024-10-01 | 7780 Silver - Russell Syndrome and Free Insulin-like Growth Factor-1 Measurements
Abstract Disclosure: R.D. Oude Engberink: None. V. van den Bogert: None. L. IJsselstijn: None. S.A. van den Berg: None. D.C. van der Kaay: None. Introduction: Silver - Russell syndrome (SRS) is a congenital condition characterized by prenatal and postnatal growth retardation. An underlying genetic cause is identified in approximately 60% of patients clinically diagnosed with SRS. The 2 main genetic alterations are loss of methylation of chromosome 11p15 (11p15 LOM) and maternal uniparental disomy of chromosome 7 (UPD(7)mat). Patients benefit from early and appropriate growth hormone (GH) treatment. However, GH treatment in SRS patients is associated with high levels (> 2 SDS) of immunoreactive Insulin-like Growth Factor-1 (IGF-1). As a result, clinicians often lower the GH dose, resulting in a suboptimal effect on growth, body composition and quality of life. There has been increased interest in measuring free IGF-1 in these conditions. Theoretically, the unbound fraction of IGF - i.e. the fraction that is readily dissociable from IGF binding proteins - is the biologically active fraction. Measurement of free IGF-1 might better reflect IGF-1 bioavailability and may be of benefit in optimizing GH treatment. Objective and methods: We explored levels of free IGF-I versus immunoreactive (total) IGF-1 in 22 SRS patients on GH treatment. Immunoreactive IGF-1 was measured on a routine immunochemistry analyzer (IDS-iSYS) and free IGF-1 was measured manually using a two-site antibody method (AnshLabs). Results: In this group of 22 SRS patients the mean immunoreactive IGF-1 was +1.96 +/- 0.48 SDS and the mean GH dose was 0.84 +/- 0.24 mg/m2/d. Subdividing into SDS categories, 45% of patients had an immunoreactive IGF-1 > 2 SDS. In this subset, 60% of patients had levels of free IGF-1 in the normal range (< 2 SDS). Further stratification into the underlying molecular defect showed that 11p15 LOM was associated with a more pronounced discrepancy between the level of immunoreactive IGF-1 (+2.64 SDS) and free IGF-1 (+0.25 SDS). Conclusion: In the majority of SRS patients on GH treatment, immunoreactive IGF-1 levels exceeded > 2 SDS, whereas free IGF-1 levels were within normal range. Measurement of free IGF-1 could provide clinicians with an additional tool to determine the dose of GH in SRS patients. Ongoing research will reveal the full potential of free IGF-1 measurements in disorders that affect the GH - IGF-1 axis. Presentation: 6/3/2024
2024-03-15 | Long-acting Growth Hormone Therapy, Rational and Future Aspects
Recombinant growth hormone (GH) is administered as daily subcutaneous injections.Daily treatment can be challenging for children/adolescents as well as for parents and/or caregivers (legal representatives, guardians of children in institutional care).Challenges associated with daily treatment may result in missing several doses and non-adherence with treatment leads to inadequate growth response.As an inadequate growth response does not meet criteria for continuing treatment, payers (commercial or public) may decide to end reimbursement.Novel long-acting GH formulations (LAGH) with extended half-life can be administered less frequently and target to improve patient convenience and consequently to improve adherence and responses to treatment.LAGH formulations can restore growth velocity and body composition as effectively as daily treatment, without unexpected adverse effects as reported in randomized clinical trials.
2022-03-11 | [Hepatopulmonary syndrome: a rare manifestation of cirrhosis in patient with diencephalic obesity and nonalcoholic fatty liver disease after surgery for craniopharyngioma].
We describe a 15-year girl, who developed panhypopituitarism and diencephalic obesity after surgical excision of craniopharyngioma, followed by nonalcoholic fatty liver disease and cirrhosis 5 years after surgery. Cirrhosis in this case manifested by hypoxia due to hepatopulmonary syndrome, and despite cure of craniopharyngioma by surgery and radiosurgery treatment and adequate hormonal substitution therapy patient died 9 years after surgery. Growth hormone substitutional therapy in patients with hypopituitarism, and steatohepatitis may decrease liver triglyceride accumulation and prevent end-stage liver disease. В статье описан клинический случай пациентки 15 лет, у которой в результате удаления краниофарингиомы, помимо несахарного диабета и пангипопитуитаризма, развилось диэнцефальное ожирение, приведшее к формированию цирроза печени. В данном случае патология печени манифестировала гепатопульмональным синдромом, характеризующимся гипоксемией, причиной которой является патологическое расширение сосудов легких, приводящее к шунтированию крови у пациентов с поражением печени. Несмотря на отсутствие рецидива опухоли после удаления и радиохирургического лечения, а также адекватную заместительную гормональную терапию, пациентка скончалась через 9 лет после операции. Заместительная терапия гормоном роста у пациентов с гипопитуитаризмом и жировым гепатозом может уменьшить аккумуляцию липидов в печени и снизить риск развития цирроза.
small molecules
2026-06-23 | ID #974 Diencephalic syndrome in an infant with low grade glioma refractory to chemotherapy a dramatic and sustained response to tovorafenib
Abstract Background Diencephalic syndrome is a rare but severe presentation of pediatric low-grade glioma (LGG), often associated with hypothalamic and optic pathway tumors in infancy and early childhood[1]. It is characterized by profound failure to thrive despite adequate caloric intake, with relative preservation of linear growth. Management is challenging, and responses to conventional chemotherapy are variable[2]. Despite low-grade histology, infant LGG with diencephalic syndrome is associated with poorer outcomes, with 5-year PFS of approximately 20%[3]. Methods We report the case of an infant diagnosed at three months of age with a large hypothalamic/optic pathway tumor with solid and cystic components, presenting with profound failure to thrive consistent with diencephalic syndrome. He underwent resection of large cystic components of the tumor and biopsy, which confirmed the diagnosis of pilomyxoid astrocytoma with a KIAA1549-BRAF fusion. Results The patient was treated with carboplatin for two months but showed early radiographic progression and leptomeningeal dissemination. Despite enteral nutritional support, he continued to show poor weight gain. Subsequent switch to vinblastine therapy failed to halt clinical or radiographic progression. In the setting of chemotherapy refractory disease, tovorafenib was initiated at six months of age. This resulted in rapid radiographic response after six weeks of treatment, associated with significant improvement in weight. Radiographic response was sustained, with improvement in both solid and cystic components of the tumor. While the patient tolerated treatment well without significant side effects, he experienced significant decrease in growth velocity while on therapy, a known side effect of tovorafenib. Conclusions This case highlights the potential for tovorafenib to induce rapid and meaningful clinical and radiographic responses in infants with diencephalic syndrome and refractory BRAF-altered low-grade glioma. Targeted therapy may represent an important treatment option for this high-risk population and is currently being evaluated in a phase 3 clinical trial. 1. Poussaint, T. Y., Barnes, P. D., Nichols, K., Anthony, D. C., Cohen, L., Tarbell, N. J., & Goumnerova, L. (1997). Diencephalic syndrome: clinical features and imaging findings. AJNR. American journal of neuroradiology, 18(8), 1499–1505. 2. Mirow, C., Pietsch, T., Berkefeld, S., Kwiecien, R., Warmuth-Metz, M., Falkenstein, F., Diehl, B., von Hornstein, S., & Gnekow, A. K. (2014). Children <1 year show an inferior outcome when treated according to the traditional LGG treatment strategy: a report from the German multicenter trial HIT-LGG 1996 for children with low grade glioma (LGG). Pediatric blood & cancer, 61(3), 457–463. https://doi.org/10.1002/pbc.24729 3. Kilday, J. P., Bartels, U., Huang, A., Barron, M., Shago, M., Mistry, M., Zhukova, N., Laperriere, N., Dirks, P., Hawkins, C., Bouffet, E., & Tabori, U. (2014). Favorable survival and metabolic outcome for children with diencephalic syndrome using a radiation-sparing approach. Journal of neuro-oncology, 116(1), 195–204. https://doi.org/10.1007/s11060-013-1284-2
2026-06-19 | Clinical application of diffusion tensor tractography in classification of pediatric optic chiasmatic gliomas: a retrospective cohort study.
The classification based on diffusion tensor tractography (DTT) has already been applied to the assessment of the optic chiasmatic glioma (OCGs), but the value of clinical application remains controversial. This study aimed to evaluate the predictive value of DTT classification for clinical phenotypes and to investigate the prognostic factors in children with OCGs. A total of 53 patients with OCGs diagnosed and admitted between July 2015 and November 2022 were included. Clinical parameters were collected from medical records. The prognosis analysis comprised clinical, endocrinologic, ophthalmologic and pathologic during different time spans. On DTT images, the tumors were divided into the inflating endophytic type, the inflating exogenous type, and the infiltrative endophytic type based on DTT features. Regression analysis detected the evaluation of classifications which was assessed by determining age, gender, weight, diencephalic syndrome diagnosis record, vision-related data, endocrine-related indicators, surgery related indicators, survival data, chemotherapy, and radiotherapy. We observed that the proportion of males in the inflating exogenous type patients (10%) was significantly lower than other two types. The inflating endophytic type patients (median 9.5 kg, 4.2∼25.4 kg) had lower body weight at surgery than other two types, as well as higher prevalence of diencephalic syndrome (DS). Postoperative chemotherapy demonstrated a statistically significant protective effect on OS and EFS (p = 0.032 and 0.017, respectively). The DTT-based classification effectively identifies the inflating endophytic subtype, which is associated with a high incidence of diencephalic syndrome, and serves as a valuable tool for preoperative surgical guidance. Combined adjuvant chemotherapy represents a decisive therapeutic strategy that significantly prolongs long-term prognosis in pediatric OCG patients.
2026-02-27 | Diencephalic Syndrome: Clinical Features, Pathophysiology, and Long-Term Outcomes.
Background/Objectives: Diencephalic syndrome (DS) is an uncommon pediatric disorder presenting with severe failure to thrive despite adequate caloric intake and preserved linear growth. First characterized by Russell, this condition predominantly affects infants under 12 months and remains diagnostically challenging. Methods: We performed a comprehensive literature review examining clinical presentation, underlying pathophysiology, associated pathology, diagnostic approaches, and long-term outcomes of DS. Results: DS typically manifests in the first year of life with profound cachexia, normal or increased appetite, preserved height velocity, and characteristic features including hyperactivity, euphorism, and visual pathway involvement. Low-grade gliomas of the hypothalamic-chiasmatic region, particularly pilocytic astrocytomas, represent the predominant underlying pathology. The pathophysiological mechanisms remain incompletely understood but likely involve complex dysregulation of hypothalamic energy homeostasis. While overall survival exceeds 90% at five years, most patients experience significant long-term morbidity including visual impairment, multiple endocrine deficiencies, and hypothalamic obesity. Diagnostic delays averaging 11 months contribute to irreversible complications. Conclusions: Early recognition of DS is essential to prevent permanent visual loss and optimize outcomes. Multidisciplinary management incorporating chemotherapy as first-line treatment for underlying gliomas has improved survival while reducing radiation-associated toxicities. However, survivors face substantial lifelong sequelae requiring comprehensive monitoring and intervention. Future research should focus on elucidating precise pathophysiological mechanisms, developing targeted molecular therapies, and improving management of hypothalamic obesity and other late effects.
2025-05-19 | Skeletal stem/progenitor cell-derived rather than osteoblast-derived IGF2 supports the development and homeostasis of skeletal system via STAT3.
Rationale: Skeletal deformities are characteristic manifestations of Silver-Russell Syndrome with mutations in insulin-like growth factor 2 (IGF2) gene serving as the most prevalent genetic abnormality. However, the mechanism by which IGF2 influence bone development and homeostasis remains unclear. Besides, the expression pattern of Igf2 and the local cells-derived Igf2 at cellular level within bone microenvironment also lacked research. Methods: ScRNA-seq analysis was obtained from Gene Expression Omnibus (GEO) and analyzed to discover the expression pattern of Igf2. Then, mice models of specific deletion of Igf2 in three different cell types by crossing Igf2 flox with Osxcre , Prx1cre and Ocncre mice respectively were established. The skeletal systems of these mice were analyzed, along with the in vitro osteogenic capacity of their bone marrow-derived mesenchymal stem cells (BMSCs). Lastly, RNA-sequencing (RNA-seq) was carried out to elucidate the underlying mechanisms, and administration of an agonist targeting the key molecule was also undertaken. Results: Igf2 was enriched in skeletal stem/progenitor cells (SSPCs) rather than osteoblasts and we have observed deformities in the femur and other skeletons in OsxCre; Igf2fl/-, Prx1Cre; Igf2fl/- but not OcnCre; Igf2fl/- mice and the deformities were induced by a reduction in osteogenesis with minimal changes in osteoclastogenesis. It is further revealed that Igf2 deletion impaired the osteogenesis via STAT3 and pharmacological activation of STAT3 could reverse the skeletal deformities. Conclusions: In summary, these finding reveals that IGF2 derived from SSPCs, rather than osteoblasts, supports the development and homeostasis of skeletal system via STAT3 signaling and targeting STAT3 might be a promising therapeutic strategy for SRS-related skeletal deformities.
2023-09-30 | Cyproheptadine as an appetite stimulant in children. Is it safe?
Background: Cyproheptadine as an appetite stimulant in children. Is it safe? This drug has been used to increase appetite in pediatric patients, regardless of their sex or the presence of pathological conditions. The effectiveness of this drug in terms of weight gain and growth is still a matter of interest. due to the diversity of conclusions regarding its mechanism of action and therapeutic results. Methods: This bibliographic review of the scientific literature focused on research in order to obtain results around scientific articles related to the use of cyproheptadine as an appetite stimulant in pediatric patients. Results: all the articles analyzed concluded that cyproheptadine is an effective medication for weight gain in pediatric patients, based on appetite stimulation, totally independent of sex and the presence of pathological states. Conclusions: Cyproheptadine is a safe medication, and adequately tolerated in all pediatric patients. It is possible to measure the improvement in weight and growth indices in patients under twelve years of age, if consumption is for at least four consecutive weeks.
antibodies
2025-09-23 | Exploring the coexistence of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis and demyelinating disorders in a pediatric case
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an immune-mediated disorder characterized by a complex neuropsychiatric syndrome and the presence of cerebrospinal fluid antibodies targeting the GluN1 subunit of the NMDAR. While well-documented, its association with demyelinating disorders—such as neuromyelitis optica, myelitis, and acute disseminated encephalomyelitis—remains rare, particularly in pediatric cases. Here, we present an unusual case of a 7-year-old female who initially exhibited area postrema syndrome, followed by acute brainstem syndrome and encephalopathy. Over two subsequent relapses within 2 years, she developed longitudinally extensive transverse myelitis, seizures, and diencephalic syndrome, alongside mild contrast-enhancing lesions in both infratentorial and supratentorial regions. Despite repeated testing, both antibodies to myelin-oligodendrocyte glycoprotein and aquaporin-4 remained negative. Subsequently, a comprehensive antibody testing protocol, including indirect immunohistochemistry on rat brain tissue and an extensive panel of both fixed and live cell-based assays was requested, confirming the presence of anti-NMDAR antibodies, along with superimposed reactivity to cerebellar granular cells. This report explores the diagnostic and therapeutic complexities of coexisting anti-NMDAR encephalitis and demyelinating disorders. The rarity of this overlap and its distinct clinical features underscore the need for further research into the immunological mechanisms underlying these conditions. • Diagnostic delay and misrecognition are common in overlapping anti-NMDAR encephalitis and demyelinating disorders, especially when initial symptoms resemble conditions such as ADEM or NMOSD. • Anti-NMDAR encephalitis should be considered in pediatric demyelinating cases presenting with prominent psychiatric or behavioral symptoms. • Long-term monitoring is essential in overlapping autoimmune syndromes due to the potential for recurrence driven by distinct immune pathways.
2024-09-25 | Diencephalic syndrome in a child with chronic malnutrition.
Russell's diencephalic syndrome is a set of signs and symptoms characterized by extreme weight loss, with no impairment of height or head circumference, without changes in intake or appetite. It is due to hypothalamic dysfunction associated with space-occupying lesions in this region. It is a rare cause of malnutrition in pediatrics, so its diagnosis is often delayed. Here we describe the case of a 17-month-old male patient with weight loss for 3 months who was admitted to the pediatric inpatient ward due to suspected intestinal malabsorption syndrome. After ruling out the most common causes of malnutrition, the patient was diagnosed with pilomyxoid astrocytoma of the brainstem.
2016-05-02 | Anti-N-methyl- d -aspartate receptor encephalitis in a patient with neuromyelitis optica spectrum disorders
We described a female patient with anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis occurring sequentially with neuromyelitis optica spectrum disorders (NMOSD). The 19-year-old patient initially presented a diencephalic syndrome with aquaporin-4 immunoglobulin G antibodies (AQP4-IgG) and brain lesions which involving bilateral medial temporal lobes and periependymal surfaces of the third ventricle on magnetic resonance imaging (MRI). Ten months later, the patient developed cognitive impairment, psychiatric symptoms and dyskinesia with left basal ganglia lesions on brain MRI. Meanwhile, the anti-NMDAR antibodies were positive in the patient's serum and cerebrospinal fluid, while the screening tests for an ovarian teratoma and other tumors were all negative. Hence, the patient was diagnosed NMOSD and anti-NMDAR encephalitis followed by low-dose rituximab treatment with a good response. This case was another evidence for demyelinating syndromes overlapping anti-NMDAR encephalitis in Chinese patients.
2013-09-04 | Children <1 year show an inferior outcome when treated according to the traditional LGG treatment strategy: A report from the german multicenter trial HIT-LGG 1996 for children with low grade glioma (LGG)
Background Children diagnosed with LGG at an age <1 year are reported to have an impaired prognosis in comparison to older patients. Analysis of this subgroup could reveal the necessity to develop risk-adapted treatment approaches. Procedure Children <1 year at diagnosis (n = 66, median age 7.3 months, 33 female, none NFI) from the HIT-LGG 1996 cohort were analyzed for risk factors for EFS, PFS and OS. Several children suffered from diencephalic syndrome (DS, n = 22) and primary dissemination (DLGG, n = 9), 50 had a supratentorial midline (SML) location. Extent of resection was complete/subtotal in 12, partial in 15, biopsy in 27. Tumors were pilocytic astrocytoma WHO grade I (n = 33), other WHO grade I (n = 14), pilomyxoid astrocytomas WHO grade II (n = 3), and neuroepithelial tumors WHO grade II (n = 4). Results One-year EFS was 34.8%. SML-localisation, minor extent of surgery, pilocytic astrocytoma, DLGG and DS were unfavorable predictive factors. No additional non-surgical therapy was applied in 24, 36 were treated with VCR/carboplatin chemotherapy, 6 with radiotherapy (5/6 brachytherapy). Ten-year-PFS-rate following non-surgical therapy was 16.7%; DS and DLGG were unfavorable factors. Ten-year-OS-rate was 72.8%, lower for children <6 months at diagnosis, with DS, or with DLGG. At last follow up in August 2011, vision in 31 living children was often severely impaired. Conclusions Children <1 year at diagnosis have a conspicuously impaired survival with current treatment approaches. Age <6 months, diencephalic syndrome and dissemination constitute risk factors for even lower PFS and OS. Treatment adaptations are needed to improve outcome and molecular genetics may explain tumor aggressiveness. Pediatr Blood Cancer 2014;61:457–463. © 2013 Wiley Periodicals, Inc.
2011-06-07 | Narcolepsy, REM sleep behavior disorder, and supranuclear gaze palsy associated with Ma1 and Ma2 antibodies and tonsillar carcinoma.
To describe a patient with diencephalic and mesencephalic presentation of a Ma1 and Ma2 antibody-associated paraneoplastic neurological disorder. Case report. The Colorado Neurological Institute Movement Disorders Center in Englewood, Colorado, and the Mayo Clinic in Rochester, Minnesota. A 55-year-old man with a paraneoplastic neurological disorder characterized by rapid eye movement sleep behavior disorder, narcolepsy, and a progressive supranuclear palsy-like syndrome in the setting of tonsillar carcinoma. Immunotherapy for paraneoplastic neurological disorder, surgery and radiotherapy for cancer, and symptomatic treatment for parkinsonism and sleep disorders. Polysomnography, multiple sleep latency test, and neurological examination. The cancer was detected at a limited stage and treatable. After oncological therapy and immunotherapy, symptoms stabilized. Treatment with modafinil improved daytime somnolence. Rapid onset and progression of multifocal deficits may be a clue to paraneoplastic etiology. Early treatment of a limited stage cancer (with or without immunotherapy) may possibly slow progression of neurological symptoms. Symptomatic treatment may be beneficial.
proteins
2025-11-20 | Growth hormone therapy in high-risk pediatric populations: Integrated growth, metabolic, and safety outcomes in SGA, preterm, and Russell–silver syndrome
Background: Growth hormone (GH) therapy is widely used to enhance growth outcomes in children with growth disorders, including those born small for gestational age (SGA), preterm infants, and individuals with Russell-Silver Syndrome (RSS). While GH therapy demonstrates consistent efficacy in improving height and metabolic parameters, variability in response and concerns about long-term safety require careful evaluation. Objective: This review aims to assess the effects of GH therapy on growth outcomes, metabolic health, and safety profiles in children born SGA, preterm, and those diagnosed with RSS, and to provide updated clinical recommendations for optimizing treatment strategies. Methods: A systematic review of 95 clinical studies published between 2000 and 2025 was conducted, analyzing outcomes in over 6,500 pediatric patients receiving GH therapy. Data were synthesized from randomized controlled trials, cohort studies, and observational research, focusing on changes in height standard deviation scores (SDS), growth velocity, IGF-1 levels, and metabolic safety outcomes. Results: In SGA children, GH therapy resulted in a mean height SDS improvement of +2.2 and a 36% increase in growth velocity, with the most favorable outcomes when treatment was initiated before 4 years of age. Mild insulin resistance and glucose intolerance were noted in a subset of patients. Preterm infants demonstrated an average height SDS gain of +1.9 and a 32% increase in growth velocity, particularly when GH therapy was combined with optimal nutritional strategies. Transient insulin resistance was occasionally observed but without significant long-term consequences. In RSS patients, GH therapy improved height SDS by +1.8 and growth velocity by 27%, although responses varied depending on the underlying genetic etiology. Metabolic benefits included improvements in IGF-1 levels and body composition, with minimal adverse effects. Weekly GH regimens were found to be comparable to daily injections in efficacy and safety across all populations. Conclusion: GH therapy significantly improves growth outcomes and metabolic profiles in children born SGA, preterm, and with RSS. Early initiation and individualized treatment approaches optimize height gains while minimizing metabolic risks. Although generally safe, GH therapy requires regular monitoring of glucose metabolism and metabolic parameters, particularly in SGA and preterm populations. Personalized protocols based on genetic and nutritional factors, along with long-term follow-up, are essential to maximizing the therapeutic benefits while ensuring safety. Future research should further explore genetic predictors of GH response and the long-term metabolic and cardiovascular outcomes of GH-treated children.
2024-10-01 | 7780 Silver - Russell Syndrome and Free Insulin-like Growth Factor-1 Measurements
Abstract Disclosure: R.D. Oude Engberink: None. V. van den Bogert: None. L. IJsselstijn: None. S.A. van den Berg: None. D.C. van der Kaay: None. Introduction: Silver - Russell syndrome (SRS) is a congenital condition characterized by prenatal and postnatal growth retardation. An underlying genetic cause is identified in approximately 60% of patients clinically diagnosed with SRS. The 2 main genetic alterations are loss of methylation of chromosome 11p15 (11p15 LOM) and maternal uniparental disomy of chromosome 7 (UPD(7)mat). Patients benefit from early and appropriate growth hormone (GH) treatment. However, GH treatment in SRS patients is associated with high levels (> 2 SDS) of immunoreactive Insulin-like Growth Factor-1 (IGF-1). As a result, clinicians often lower the GH dose, resulting in a suboptimal effect on growth, body composition and quality of life. There has been increased interest in measuring free IGF-1 in these conditions. Theoretically, the unbound fraction of IGF - i.e. the fraction that is readily dissociable from IGF binding proteins - is the biologically active fraction. Measurement of free IGF-1 might better reflect IGF-1 bioavailability and may be of benefit in optimizing GH treatment. Objective and methods: We explored levels of free IGF-I versus immunoreactive (total) IGF-1 in 22 SRS patients on GH treatment. Immunoreactive IGF-1 was measured on a routine immunochemistry analyzer (IDS-iSYS) and free IGF-1 was measured manually using a two-site antibody method (AnshLabs). Results: In this group of 22 SRS patients the mean immunoreactive IGF-1 was +1.96 +/- 0.48 SDS and the mean GH dose was 0.84 +/- 0.24 mg/m2/d. Subdividing into SDS categories, 45% of patients had an immunoreactive IGF-1 > 2 SDS. In this subset, 60% of patients had levels of free IGF-1 in the normal range (< 2 SDS). Further stratification into the underlying molecular defect showed that 11p15 LOM was associated with a more pronounced discrepancy between the level of immunoreactive IGF-1 (+2.64 SDS) and free IGF-1 (+0.25 SDS). Conclusion: In the majority of SRS patients on GH treatment, immunoreactive IGF-1 levels exceeded > 2 SDS, whereas free IGF-1 levels were within normal range. Measurement of free IGF-1 could provide clinicians with an additional tool to determine the dose of GH in SRS patients. Ongoing research will reveal the full potential of free IGF-1 measurements in disorders that affect the GH - IGF-1 axis. Presentation: 6/3/2024
2024-03-15 | Long-acting Growth Hormone Therapy, Rational and Future Aspects
Recombinant growth hormone (GH) is administered as daily subcutaneous injections.Daily treatment can be challenging for children/adolescents as well as for parents and/or caregivers (legal representatives, guardians of children in institutional care).Challenges associated with daily treatment may result in missing several doses and non-adherence with treatment leads to inadequate growth response.As an inadequate growth response does not meet criteria for continuing treatment, payers (commercial or public) may decide to end reimbursement.Novel long-acting GH formulations (LAGH) with extended half-life can be administered less frequently and target to improve patient convenience and consequently to improve adherence and responses to treatment.LAGH formulations can restore growth velocity and body composition as effectively as daily treatment, without unexpected adverse effects as reported in randomized clinical trials.
2022-03-11 | [Hepatopulmonary syndrome: a rare manifestation of cirrhosis in patient with diencephalic obesity and nonalcoholic fatty liver disease after surgery for craniopharyngioma].
We describe a 15-year girl, who developed panhypopituitarism and diencephalic obesity after surgical excision of craniopharyngioma, followed by nonalcoholic fatty liver disease and cirrhosis 5 years after surgery. Cirrhosis in this case manifested by hypoxia due to hepatopulmonary syndrome, and despite cure of craniopharyngioma by surgery and radiosurgery treatment and adequate hormonal substitution therapy patient died 9 years after surgery. Growth hormone substitutional therapy in patients with hypopituitarism, and steatohepatitis may decrease liver triglyceride accumulation and prevent end-stage liver disease. В статье описан клинический случай пациентки 15 лет, у которой в результате удаления краниофарингиомы, помимо несахарного диабета и пангипопитуитаризма, развилось диэнцефальное ожирение, приведшее к формированию цирроза печени. В данном случае патология печени манифестировала гепатопульмональным синдромом, характеризующимся гипоксемией, причиной которой является патологическое расширение сосудов легких, приводящее к шунтированию крови у пациентов с поражением печени. Несмотря на отсутствие рецидива опухоли после удаления и радиохирургического лечения, а также адекватную заместительную гормональную терапию, пациентка скончалась через 9 лет после операции. Заместительная терапия гормоном роста у пациентов с гипопитуитаризмом и жировым гепатозом может уменьшить аккумуляцию липидов в печени и снизить риск развития цирроза.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
0 orphan drug designations.
0 orphan drug designations.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.